
Ahmed A F Abdelhakeem

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1046208/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	15.2	134
2	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut, 2021, 70, 2055-2065.	6.1	24
3	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer, 2020, 23, 904-912.	2.7	15
4	Dietary Nâ€Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USAâ€Based Study. Hepatology, 2021, 74, 3161-3173.	3.6	10
5	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Annals of Surgery, 2021, 273, 751-757.	2.1	8
6	Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients, 2021, 13, 2011.	1.7	8
7	Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Medicine, 2021, 10, 7308-7319.	1.3	6
8	A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nature Reviews Clinical Oncology, 2019, 16, 9-10.	12.5	4
9	Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers, 2021, 13, 420.	1.7	3
10	Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology, 2021, 99, 659-664.	0.9	2
11	Distribution of insulin growth factor-1 (IGF-1) binding proteins in hepatocellular carcinoma with and without cirrhosis Journal of Clinical Oncology, 2019, 37, 193-193.	0.8	1
12	SAT-451-Gallbladder disease in the absence of cirrhosis is a significant risk factor for hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e831.	1.8	0
13	Localized diffuse-type gastric adenocarcinoma: Influence of baseline positron emission tomography on survival and therapy response Journal of Clinical Oncology, 2021, 39, 176-176.	0.8	0
14	IGF-Child-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy Journal of Clinical Oncology, 2019, 37, 223-223.	0.8	0
15	Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma Journal of Clinical Oncology, 2019, 37, e15526-e15526.	0.8	0
16	Abstract 5046: Gallbladder disease and the risk of hepatocellular carcinoma: US case-control study. , 2019, , .		0
17	Trastuzumab + fluoropyrimidine maintenance in the frontline setting for non-progressing advanced HER-2 positive gastroesophageal adenocarcinoma Journal of Clinical Oncology, 2020, 38, 291-291.	0.8	0
18	Survival benefit of oophorectomy in stage IV gastric cancer patients with Krukenberg tumors Journal of Clinical Oncology, 2020, 38, e16566-e16566.	0.8	0

#	Article	IF	CITATIONS
19	Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology, 2020, 98, 884-888.	0.9	0
20	Abstract 5046: Gallbladder disease and the risk of hepatocellular carcinoma: US case-control study. , 2019, , .		0